Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 20;10(12):e30398.
doi: 10.2196/30398.

Study of Treatment and Reproductive Outcomes Among Reproductive-Age Women With HIV Infection in the Southern United States: Protocol for a Longitudinal Cohort Study

Affiliations

Study of Treatment and Reproductive Outcomes Among Reproductive-Age Women With HIV Infection in the Southern United States: Protocol for a Longitudinal Cohort Study

Anandi N Sheth et al. JMIR Res Protoc. .

Abstract

Background: Nearly a quarter of the 1.1 million individuals with HIV in the United States are women. Racial and ethnic minority women in the Southern United States are disproportionately impacted. Reproductive-age women with HIV are prone to poor HIV outcomes but remain underrepresented in HIV research. We will answer contemporary questions related to the health outcomes in this population by enrolling a prospective cohort of reproductive-age women with and without HIV in the Southern United States.

Objective: The Study of Treatment and Reproductive Outcomes (STAR) will enroll and retain 2000 reproductive-age women with and without HIV. The STAR will leverage the infrastructure of the US-based Multicenter AIDS Cohort Study (MACS)/Women's Interagency HIV Study (WIHS) Combined Cohort Study, comprising the WIHS (a cohort of women with and at risk for HIV, which began in 1993), and the MACS (a cohort of gay and bisexual men with and at risk for HIV, which began in 1984). Although the advancing age of the participants enrolled in the MACS/WIHS Combined Cohort Study provides an opportunity to address the questions related to HIV and aging, the research questions pertinent to the reproductive years must also be addressed. The STAR will conduct high-priority scientific research in key areas with the overall aim of addressing the unique needs of reproductive-age women with HIV.

Methods: The STAR is a prospective, observational cohort study that will be conducted at 6 sites in the United States-Atlanta, Georgia; Birmingham, Alabama; Jackson, Mississippi; Chapel Hill, North Carolina; Miami, Florida; and Washington, District of Columbia. Visits will occur semiannually for 2 years, with additional visits for up to 5 years. At each visit, the participating women will complete a structured interview for collecting key demographic, psychosocial, and clinical variables, and undergo biospecimen collection for laboratory testing and repositing (blood, urine, hair, vaginal, anal, and oral specimens). Pregnant women and infants will undergo additional study assessments. The initial scientific focus of the STAR is to understand the roles of key social determinants of health, depression, reproductive health, and oral health on HIV and pregnancy outcomes across the reproductive life span.

Results: Enrollment in the STAR commenced in February 2021 and is ongoing.

Conclusions: Through in-depth, longitudinal data and biospecimen collection, the newly initiated STAR cohort will create a platform to answer scientific questions regarding reproductive-age women with and without HIV. STAR will be uniquely positioned to enable investigators to conduct high-impact research relevant to this population. Building on the legacy of the MACS and WIHS cohorts, the STAR is designed to foster multidisciplinary collaborations to galvanize scientific discoveries to improve the health of reproductive-age women with HIV and ameliorate the effects of the HIV epidemic in this population in the United States.

Keywords: HIV; depression; longitudinal cohort study; oral health; women’s health.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: DW has engaged in consulting for PRI Healthcare Solutions on behalf of Sanofi Pasteur on subjects unrelated to this work. MLA receives honorarium from the following sources (unrelated to this work): Merck Inc (educational lecture fees) and Senhwa pharmaceuticals (Data Safety Monitoring Board member). AAA has received consulting fees and funds for research to her institution from Merck and Gilead.

Figures

Figure 1
Figure 1
Southern United States with county-level rates of women with HIV per 100,000 persons in 2018. Source: AIDSVu, Emory University, Rollins School of Public Health [29]. *Data not shown to protect privacy because of a small number of cases and/or a small population. **State health department, per its HIV data rerelease agreement with CDC, requested not to release data to AIDSVu. There are no county-level maps for Alaska, District of Columbia, and Puerto Rico because there are no counties in these states. STAR: Study of Treatment and Reproductive Outcomes.
Figure 2
Figure 2
Overview of the Study of Treatment and Reproductive Outcomes objectives and study visits.

Similar articles

Cited by

References

    1. HIV Surveillance Report, 2017; vol. 29. Centers for Disease Control and Prevention. 2018. [2019-04-14]. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveil... .
    1. Rana AI, Gillani FS, Flanigan TP, Nash BT, Beckwith CG. Follow-up care among HIV-infected pregnant women in Mississippi. J Womens Health (Larchmt) 2010 Oct;19(10):1863–7. doi: 10.1089/jwh.2009.1880. http://europepmc.org/abstract/MED/20831428 - DOI - PMC - PubMed
    1. Momplaisir Florence M, Storm Deborah S, Nkwihoreze Hervette, Jayeola Olakunle, Jemmott John B. Improving postpartum retention in care for women living with HIV in the United States. AIDS. 2018 Jan 14;32(2):133–142. doi: 10.1097/QAD.0000000000001707. http://europepmc.org/abstract/MED/29194122 - DOI - PMC - PubMed
    1. Firnhaber C, Smeaton LM, Grinsztejn B, Lalloo U, Faesen S, Samaneka W, Infante R, Rana A, Kumarasamy N, Hakim J, Campbell TB. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clinical Trials. 2015 May 15;16(3):89–99. doi: 10.1179/1528433614z.0000000013. - DOI - PMC - PubMed
    1. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. 2007 Jun;4(2):106–19. doi: 10.1016/s1550-8579(07)80025-8.S1550-8579(07)80025-8 - DOI - PubMed